Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04093895 · ClinicalTrials.gov registry record · Phase 2
Trial to Evaluate Safety, Tolerability, Efficacy of PerioSept® as Adjunct to SRP in Subjects With Periodontitis
A Phase 2 study, sponsored by Geistlich Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
NCT04093895: Completed Phase 2 study, sponsored by Geistlich Pharma.
NCT04093895 is a Phase 2 study that has completed, run by Geistlich Pharma. The registered enrollment target is 12 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (91% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04093895, a Phase 2 study, has completed, sponsored by Geistlich Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
Study Summary
A Phase 2, uncontrolled, open-label, single arm study to evaluate the safety, tolerability and efficacy of PerioSept® (3%) as adjunct to Scaling and Root Planing in subjects with periodontitis.
Primary Outcome
Mean probing pocket depth (PPD) reduction (mm) of all study pockets (pockets with PPD \> 6 mm and bleeding on probing (BOP) at baseline on target teeth) at subject level and across all subjects
Interventions
- DRUG PerioSept(r)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2019-08-26 |
| Est. Completion | 2020-09-25 |
| Phase | Phase 2 |
What the finished NCT04093895 record still lists
NCT04093895 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (91% lower).
The record links to 0 conditions, and to 1 intervention - of which PerioSept(r) is the first listed.
NCT04093895 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04093895 about?
NCT04093895 is a clinical study titled "Trial to Evaluate Safety, Tolerability, Efficacy of PerioSept® as Adjunct to SRP in Subjects With Periodontitis". A Phase 2, uncontrolled, open-label, single arm study to evaluate the safety, tolerability and efficacy of PerioSept® (3%) as adjunct to Scaling and Root Planing in subjects with periodontitis.
What is the current status of trial NCT04093895?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2019-08-26. Estimated completion is 2020-09-25.
What interventions are being tested in trial NCT04093895?
The interventions under investigation include: PerioSept(r) (DRUG).
Who is sponsoring clinical trial NCT04093895?
This trial is sponsored by Geistlich Pharma, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04093895's enrollment target sits among peer trials
12 1948th of 2000 higher than 34 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI